Print

The Abramson Cancer Center of the University of Pennsylvania

As patients and their advocate/caregivers become more educated about their cancer diagnosis, they may begin reading more detailed information, including research papers and OncoLink conference coverage. The alphabet soup of abbreviations and terms used in these studies can be tough to decipher. Many healthcare providers have taken college level courses to learn this terminology and still have a difficult time explaining it. This list contains some of the terms commonly seen in studies, and may help to better interpret the results.

To start, you should understand the basics about clinical trials. OncoLink has several articles about clinical trials and participating in them. A clinical trial is a study that compares group(s) of patients receiving a new or experimental intervention (the experimental group) with group(s) receiving the standard of care or placebo (the control group). The intervention can be a medication, support group, some type of education, a vaccine, or any treatment. All trial participants, no matter which group they are in, must receive and sign a consent form and have the trial explained to them by the physician or nurse. All trials are reviewed by an impartial group called the Institutional Review Board (IRB) for safety and quality control.

A clinical trial cannot test everyone in the population, so the group of patients being studied is an estimate for how the entire population would respond to the therapy. Statistical tests are used to analyze the study results, which can include survival rates, survival in months/years, time to disease progression, and quality of life measures, among other things. Researchers use different measures and tests depending on what is being analyzed. These terms are some that you may see used in trial results.

**Clinical Benefit Rate: **Also called CBR, this value is the total of all complete responders, all partial responders, and those with stable disease for 6 months or more. Basically, this is the number of patients who derived any benefit from the intervention.

**Complete Responders: **This is the number of patients whose tumors disappeared after the intervention. This might also be called complete remission.

**Confidence Interval: **Any result in a clinical trial is only an estimate of the entire population. A study gives a confidence interval (CI) as a range that would reflect the true effect on the entire population. This value tells us how precise our statistical calculation is, and gives us an estimate of the amount of error involved in our data. For example, in "overall survival of 81% (95% CI 78%-83%)”: 81% is the mean overall survival of the group, with a 95% likelihood that the population’s result will fall into the range of 78%-83% (the size of the range is called the standard error). A 95% CI is equivalent to a p value of 0.05, a 90% CI is equivalent to a p value of 0.01.

**Control Group: **This is the group of patients that are being used to compare to the experimental group. In some studies, the control group might be a group of healthy individuals who are similar in age and other demographic characteristics; in others, it may be a group of patients with the same disease, receiving the standard therapy.

**Double Blind: **A trial uses double blinding to prevent the patient or his/her physician from knowing what treatment the patient is getting. This prevents any "placebo effect”, or the chance that the result is due to the patient or doctor thinking they are getting the medication or not. Double blinding can be done by giving the control group a sugar pill, while the experimental group gets the new medication, and the pharmacist being the only one to know who gets what (and he or she isn’t telling!). A study can be blinded (i.e. single blinding) by allowing the physician to know who is getting the experimental drug, but keeping the patients from knowing what they are getting.

**Experimental Group: **This is the group of patients that got the intervention being tested. It is compared to a control group, which may get the standard therapy or placebo.

**Hazard Ratio: **The HR is a way to summarize the difference between two survival curves. In a trial, survival is plotted on a graph with two curves, one representing the experimental group, one the control group. The rate of survival changes over time. The HR is a numerical representation of a comparison between the two survival curves. If the two survival curves are the same, the HR is 1 and there is no survival difference between the two groups. An HR over 1 means the experimental treatment is less effective than the control treatment and therefore detrimental to survival; the higher the value, the less effective the experimental therapy is in regard to survival. If the HR is below 1, survival is greater with the experimental therapy; the lower the value, the more survival benefit from the experimental therapy.

**Median**: The median is the "middle of the pack." In this example of years since treatment, the median is the time when half of the patients have had more years since treatment and half have less. For instance, if the patients were 2, 4, 6, 10.8, 12, 12 and 14 years since treatment, 10.8 is the mid- point, or the median. This is different from the mean, which would be the average time since treatment.

**Mean**: The mean is the average of the group.

**Objective Tumor Response Rate: **This is the total number of partial responders and complete responders combined.

**Overall Survival: **Also called OS, this refers to a percent, number or time of survival of all patients, regardless of whether they are disease free or have active disease.

**P Value: **P value is a difficult term to understand, and requires some understanding of the null hypothesis. The null hypothesis states that there is no difference between the two groups being studied and the p value is used to prove or disprove this. P value is a statistical test used to measure how much evidence there is against the null hypothesis and prove statistical significance. Researchers use a p value of 0.05 or less to say that the intervention had an effect and is statistically significant. So a p value of <0.001 would be statistically significant. But, you can remember that the lower the p value, the more convincing the result. (See "power” for another caveat)

**Partial Responders: **This is the number of patients whose tumors decreased in size. Some studies will dictate what percentage of decrease is required to count as a partial response.

**Placebo Controlled: **A placebo-controlled trial compares the experimental intervention to a placebo. In this method, everyone gets something; for example, the experimental group would take 2 doses a day of the medication being tested. The placebo group would take 2 doses of a sugar pill a day, although both groups would be "blinded”, meaning they do not know if they are getting the sugar pill or the real medication.

**Power: T**he power of a study is its ability to detect a real difference in the results of the study groups. It is used in planning a study and dictates the number of participants needed to detect a predetermined difference in the results. If a study is "underpowered” because it has too few participants, it may not be able to detect a difference. It can be a reason that the resulting p value is not statistically significant.

**Progression Free Survival: **Also called PFS, this refers to the number, percent, or time of survival (in days, months, or years) before the patient’s disease progresses/ recurs.

**Randomized: **In a randomized trial, participants are randomly assigned to one of the treatment arms. This is often done by a computer, with the process being similar to the flip of a coin. The patients or their physicians do not have any choice or control over which treatment group they are assigned to.

**Retrospective: **A retrospective study looks back at what effect something had on a group. For example, if I want to know how symptoms of lung cancer predict stage at diagnosis, I could look back at the records of people with lung cancer to determine what symptoms they reported when they were diagnosed, and correlate this with their stage. This is not as reliable as a trial that follows people going forward over time.

**Stable Disease: **This is the number of patients whose tumors did not grow or shrink. It is typically used with a defined time period; for example, the trial may specify "stable disease for 6 months or more”.

**Statistically significant**: This term is used to determine whether the intervention (drug, support group, vaccine, etc) is the cause of the statistical difference in outcomes between the two studied groups, or if the outcomes could have differed just by chance. Researchers use a p value of 0.05 or less to say that the intervention had an effect and is statistically significant. It is not enough to compare the result of one group versus the result of the other group. Many other variables are taken into account, including the number of participants, follow-up time, and how the outcome applies to all the participants. Having a statistically significant value is crucial in order for a given clinical study to determine whether or not the intervention is effective. You will see many studies report results that "trend towards statistical significance." While this trend can help generate further research questions (called hypothesis generating), it does not mean an intervention was effective. Having said that, just because an intervention does not meet the criteria for statistical significance, does not automatically mean it doesn’t carry some clinical importance for a given patient or group of patients.

OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.

**Information Provided By:** www.oncolink.org | © 2016 Trustees of The University of Pennsylvania